Abstract. Acidic isoferritins, which under normal conditions are released from monocytes and macrophages, have a suppressive effect in vitro on granulocytemacrophage, erythroid, and multipotential hematopoietic progenitor cells. Cell interactions modulating the release of acidic isoferritin-inhibitory activity (AIFHA) from human monocytes were investigated using the bone marrow granulocyte-macrophage progenitor cells as a target cell assay for assessing AIFIA. Monocytes, in the absence of T lymphocytes, released AIFIA when allowed to condition culture medium at 10 or higher concentrations ofmonocytes/ml. However, subpopulations of T lymphocytes modulated the release ofAIFIA from monocytes. OKT8+-and OKT4+-T lymphocytes were obtained from E-rosettepositive lymphocytes by using T lymphocyte subset-specific monoclonal antibodies in either a complement-dependent cytotoxicity test to select negatively for the cells or by selection using a "panning" procedure. OKT8+ 
ofAIFIA from concentrations of 103 monocytes/ml which did not release measurable amounts of AIFIA by themselves. The release of AIFIA from monocytes involved HLA-DR+-monocytes and -T lymphocytes. Pulsing monocytes with monoclonal antibodies to framework determinants on HLA-DR molecules, in the absence of complement, did not influence the constitutive release of AIFIA. Pulsing monocytes or T lymphocyte subpopulations with such antibodies, in the absence of complement, blocked the suppressing and inducing activities of the appropriate subpopulations ofT lymphocytes. Monoclonal antibodies to common determinants shared by HLA-A, B, and C molecules did not block these cellular interactions. Treating monocytes and T lymphocytes in a complement-dependent cytotoxicity test with dilutions of the anti-HLA-DR antibodies that did not block the cellular interactions removed the populations of monocytes constitutively releasing AIFIA and the T lymphocyte subsets modulating this release. Modulation ofthe release of AIFIA from monocytes by T lymphocyte subpopulations required the use of autologous cells, cells from HLA-identical siblings, or unrelated donors matched for HLA-DR. Matching for only one HLA haplotype gave partial responses and this was seen in testing cells from related individuals as well as among unrelated test combinations. These cellular interactions were not detected with HLA-DR-incompatible cells differing for two HLA-DR antigens. Admixture of such HLA-DR-incompatible allogeneic cells did not interfere with the regulation of AIFIA release in the autologous cell interactions. Thus, release of AIFIA from monocytes is restricted genetically by HLA-DR at the level of T lymphocyte-monocyte in- teractions. The genetic determinants on the HLA-class II molecules that induce stimulation in vitro in mixed
Introduction
Stimulatory and inhibitory interactions, manifested by cells and cell-derived products, have been implicated in the regulation of pluripotential and lineage-committed bone marrow hematopoietic progenitor cells in vitro and in vivo (1, 2) . Some of these regulatory interactions are aberrant during leukemia and may be associated with the progression of the disease (1, 2).
A leukemia-associated inhibitory activity (LIA)' (3) (4) (5) (6) that suppresses the formation in vitro of colonies and clusters from HLA-DR' (Ia-like antigen') subpopulations of cycling colonyforming unit-granulocyte-macrophage (CFU-GM) (7) (8) (9) , multipotential colony-forming unit-granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM) (10) , and burst-forming units erythroid (BFU-E) (10) progenitor cells of normal donors, but not from HLA-DR-cycling progenitor cells from patients with leukemia (7) , has been identified as acidic isoferritins (1 1). Acidic isoferritin-inhibitory activity (AIFIA), under normal conditions, is produced and released from bone marrow and blood cells of the mononuclear phagocyte lineage (monocytes and macrophages) (12) but is found in greater concentrations in cells from patients with leukemia (3) (4) (5) (6) . Blast progenitor cells from patients with leukemia are insensitive to inhibition by AIFIA (13) and abnormalities in AIHA interactions have been detected in mice infected with Abelson (12, 14) and Friend virus (15, 16) . We had suggested that AIFIA might be physiologically relevant (1 1, 12) and that it might confer a proliferative advantage to abnormally responsive leukemia progenitor cells and thus also be relevant pathologically (3-7, 11, 12, 14) . Others have also suggested its relevance in leukemia (13, 15) . Information on how the release of AIFIA from monocytes is controlled under normal conditions would help us to better understand its potential relevance physiologically and pathologically. Lymphocyte-monocyte interactions (17-21) and the involvement of the human HLA-DR and murine Ia-antigens have been implicated in the regulation ofimmune responsiveness (17, 18, 22) and in the regulation of myelopoiesis (7) (8) (9) (10) (23) (24) (25) (26) (27) ). The present study demonstrates that the modulation of the release of AIFIA from human monocytes is restricted genetically by HLA-DR at a subpopulation level ofT lymphocyte-monocyte interactions.
1. Abbreviations used in this paper: AIFIA, acidic isoferritin-inhibitory activity; BFU-E, burst-forming unit-erythroid; C', complement; CFU-GM, colony-forming unit-granulocyte-macrophage; CFU-GEMM, colony-forming unit-granulocyte, erythroid, macrophage, megakaryocyte; CM, conditioned medium; E+, E-, E-rosette positive and negative, respectively; FBS, fetal bovine serum; GM-CSF, granulocyte-macrophage colony-stimulating factors; LIA, leukemia-associated inhibitory activity; MLC, mixed lymphocyte culture; PBMC, peripheral blood mononuclear cells. (32) and OKT8, which recognizes the human suppressor-cytotoxic T lymphocyte subset (33) , were purchased from Ortho Diagnostic Systems, Inc. OKT9, which recognizes transferrin receptors (34) and OKTI la, which recognizes E-rosette+ cells (35) Complement-dependent cytotoxicity and complement-independent studies. These procedures have been described previously (23, 25 20) were observed under these conditions when no exogenous stimulatory factors were supplied. GM-CSF was present in medium conditioned by either the GCT cell line (Gibco Laboratories) (40) or the 5637 cell line (41) . These sources of GM-CSF are free of AIFIA, stimulate maximal clonal growth, and allow for increased detection of the sensitivity of CFU-GM to AIFIA (12, 42) . Test and B14 in addition to DRI, while the cell combination RM and NF only shared DRI. The one-way MLC testing between the HLA haploidentical and HLA-DR haploidentical unrelated combination were strongly positive for GK:RDx; RB:RDx; MZ:NFx; LR:NFx; and NF:RMx (x denotes x-irradiated stimulating cells). The combinations RD:GKx; RD:RBx; NF:MZx; NF:LRx and NF:RMx demonstrated a weak positive response (relative response 10-25%) compatible with a HLA-D typing response (43) . These typing responses were obtained because of the HLA-D/DR homozygosity of the stimulating cells GK, RB (i.e., HLA-Dw3/DR3), MZ, LR, and RM (i.e., HLA-Dwl/DRI).
Methods

Results
AIFIA derives from an HLA-DR+ subpopulation of human monocytes. It has been shown that monocytes and macrophages under normal conditions, contain and release AIFIA (12) . To define the cellular source ofthis release further, adherent mononuclear blood cells (90-95% monocytes, <2% PMN, 3-9% lymphocytes) were treated with control medium, C' or monoclonal antibodies in the presence of C', to remove T, HLA-DR+-and Mac-1 '-cells. AIFIA release from monocytes was first detected after 12-15 h, was maximal after 24-48 h and was no longer detected after 3-4 d. The data in Fig. 1 represent the average results of assaying medium conditioned by these treated cells from 3 to 5 normal donors for 24 h, undiluted and diluted, for inhibition ofcolony and cluster formation ofbone marrow cells stimulated by an exogenous source of GM-CSF. Undiluted CM from 106 adherent mononuclear cells (monocytes)/ml reduced significantly (P < 0.0005) colony and cluster formation by~-50% and dilution ofthis CM resulted in a plateau curve of inhibition at -50% over 7 log dilutions, a curve similar to that detectable with AIFIA (11) . CM from I05 monocytes/ml released 2 log units less activity and CM from I04 monocytes/ml demonstrated plateau levels of inhibitory activity only when undiluted. Inhibitory activity was not detected in CM prepared from 102 to 103 monocytes/ml. Results were similar whether the adherent mononuclear blood cells were treated with control medium or C'. The inhibitory activity present in CM from I0 to 106 monocytes/ml was inactivated by pretreatment of CM with goat antihuman heart ferritin antiserum, which is relatively specific for the acidic isoferritins (1 1). The inhibitory activity was also inactivated by pretreatment of CM with goat anti-human heart ferritin antiserum that was first adsorbed with basic isoferritins and which then did not recognize the basic isoferritins but did recognize the acidic isoferritins (data not shown). This substantiates that the inhibitory activity is of the acidic isoferritin type. Complete removal of the remaining 1-4% T cells from the adherent mononuclear cell fraction using monoclonal antibodies (i.e., T101, OKT3, OKT9, and OKT1 la) in the presence of C' had no effect on the release of AIFIA from 106 adherent mononuclear cells/ml. (Fig. 2 A) and 103 monocytes/ml (Fig. 2 B) are demonstrated. The adherent mononuclear cell fraction was depleted of T cells by treatment with OKT3 plus C'. The OKT8+- The influence ofthe subpopulations of T lymphocytes, which were obtained by complement-dependent cytotoxicity, on release ofAIFIA from monocytes was substantiated by using OKT8+E' and OKT4+E' cells obtained by sorting for these cells using a panning procedure (38) (Fig. 3) . The release of AIFIA from 105 monocytes was suppressed completely by 105 OKT8' cells and suppressed slightly by 104 OKT8+ cells (Fig. 3 A) (Fig. 3 B) . Fig. 4 . Pulsing monocytes with anti-HLA-DR did not prevent the release ofAIHA from I0O monocytes/ml. Pulsing monocytes alone or lymphocytes alone with anti-HLA-DR or leaving the antibody in with the monocyte-lymphocyte mixtures blocked both the suppression effect (Fig. 4 A) and the induction effect (Fig. 4 B) . Anti-HLA-DR in the absence of C' blocks the suppressive and inductive influences of the T lymphocyte subpopulations on release of AIFIA from monocytes. Thus, it was necessary to determine if removal of both influences by pretreating the individual T lymphocyte or monocyte populations with anti-HLA-DR in the presence of C' was due to actual kill of the cells or to a blocking action of the anti-HLA-DR. As shown in Fig. 6 , removal of the suppressive and inductive influences of the T lymphocyte subsets was apparent when the cells were pretreated in the presence of C' with a dilution of anti-HLA-DR that did not in the absence of C' block the cellular interactions. Release ofAIFIA from I0 monocytes was not influenced by pretreating (Fig. 6 A) . 1,000 monocytes, pretreated with anti-HLA-DR in the absence or presence of C' did not release AIFIA (Fig. 6 B) . The suppressive (Fig. 6 A) and inductive ( Fig. 6 B) influences of lymphocytes on release of AIFIA from monocytes was blocked by pretreating the lymphocytes or monocytes with a 1:50, but not with a 1:200 dilution, of anti-HLA-DR in the absence of C'. Pretreating the cells with a 1:200 dilution of anti-HLA-DR in the presence of C' ablated the influences of the lymphocytes.
To determine the specificity of the blocking interaction with anti-HLA-DR in the absence of C', two monoclonal antibodies against HLA-A, B, C were used in a comparative assay. Neither of these monoclonal HLA-A, B, C antibodies was capable of blocking the OKT8-enriched lymphocyte cell suppression of AIFIA release from 105 monocytes (Fig. 6 A) or the OKT4-enriched lymphocyte cell induction of AIFIA release from 103 monocytes (Fig. 6 B) . The results shown are for antibody KF16 1, but similar results were obtained with the commercial antibody.
The results shown above suggested further that HLA-DR antigenic determinants were probably involved in the modulation of release of AIFIA.
HLA-DR compatibility of lymphocytes and monocytes is necessary for lymphocyte modulation of AIFIA release from monocytes. To elucidate further the role of HLA-DR in this situation, a series of experiments were set up to determine if these cellular interactions were restricted genetically at the level of HLA-DR antigenic determinants. In the first series of experiments, the influence of autologous vs. HLA-different allo- geneic cell combinations was assessed (Fig. 7) . In the second series, the influence of allogeneic cells from HLA genotypically identical siblings and first degree relatives was determined (Fig.  8) . In the third series, the influence of allogeneic cells from unrelated donors completely matched at HLA or HLA-DR or donors who were haploidentical for HLA or HLA-DR alone was evaluated (Fig. 9) . The curves in Fig. 7 are the average results of CM from 21 different blood donors. A total of six different marrow targets were used. The suppression of AIFIA release from 105 monocytes/ml (Fig. 7 A) and the induction of AIFIA release from 103 monocytes/ml (Fig. 7 B) was apparent with autologous lymphocytes, but not with allogeneic lymphocytes that were HLA different. The lack of modulatory influence with the HLA-different allogeneic combinations was apparent regardless of which donor supplied the monocyte fraction and which donor supplied the lymphocyte fraction.
An assessment ofthe cell interactions with cells from related donors is shown in Fig. 8 and includes four donors who were HLA genotypically identical siblings and four donors who were HLA haploidentical first degree relatives. The suppression of AIFIA release from 105 monocytes/ml (Fig. 8 A) and the induction of AIFIA release from 103 monocytes/ml (Fig. 8 B) was complete with the HLA-identical lymphocytes and monocytes. Partial suppression (Fig. 8 A) and partial induction (Fig. 8 B) was noted with the haploidentical cell combinations. The partial responses in the HLA-haploidentical cell combinations were similar regardless of which haploidentical donor supplied the lymphocytes and which one supplied the monocytes.
Interactions involving cell mixtures from unrelated donors matched at HLA or HLA-DR are given in Fig. 9 . The HLA combinations used are shown in the legend to Fig. 9 there was complete suppression of AIFIA release from 105 monocytes/ml (Fig. 9 A) and induction of AIFIA release from IO' monocytes/mI (Fig. 9 B) . There was partial suppression (Fig.   9 A) and induction ( Fig. 9 B) when cells were HLA haploidentical. The results were similar using HLA-DR haploidentical cells regardless ofwhich haploidentical donor supplied the monocyte fraction and which donor supplied the lymphocyte fraction. The experiments shown in Figs. 7-9 demonstrated that the lymphocytes and monocytes had to have been matched for at least one HLA-DR determinant in order for the lymphocyte subpopulations to suppress or induce AIFIA release from monocytes. The suppression and induction of AIFIA release from monocytes by their HLA-identical or HLA-DR-identical allogeneic lymphocyte subpopulation were blocked by pulsing the monocytes with anti-HLA-DR, in the absence of C', before culturing the monocytes with the lymphocyte subpopulations. Similarly, the partial suppression and induction of AIFIA release from monocytes by HLA haploidentical allogeneic lymphocytes were blocked also by anti-HLA-DR antibodies (11 combinations each for suppression and induction of AIFIA release; data not shown).
Experiments were done to determine if HLA-nonidentical allogeneic cells could interfere with autologous cell interactions (Fig. 10) and if the allogeneic cell interactions led to the production of inactivators of AIFIA or to the release of factors that could suppress or induce AIFIA release from monocytes. 105 OKT8+-enriched lymphocytes from one cell donor did not sup- (25) (26) (27) , transferrin (26, 27, 46) , AIFIA (7-10, 26, 27) 
